Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis COMFORT-I

Ruxolitinib provided clinical benefit for patients with myelofibrosis in clinical trials. However, assessing benefit in community settings remains challenging. This exploratory analysis evaluated results from the phase III COMFORT (Controlled Myelofibrosis Study With Oral JAK inhibitor Treatment)-I...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Carole B., Komrokji, Rami S., Mesa, Ruben A., Sun, William, Montgomery, Michael, Verstovsek, Srdan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148882/
https://www.ncbi.nlm.nih.gov/pubmed/28606598
http://dx.doi.org/10.1016/j.clml.2017.05.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148882/
https://www.ncbi.nlm.nih.gov/pubmed/28606598
http://dx.doi.org/10.1016/j.clml.2017.05.015

Ejemplares similares